
Aligos Therapeutics (ALGS) Stock Forecast & Price Target
Aligos Therapeutics (ALGS) Analyst Ratings
Bulls say
Aligos Therapeutics is poised for a positive trajectory due to its evolving pipeline, particularly with ALG-055009, which has demonstrated significant liver fat reduction and beneficial lipid effects without the gastrointestinal liabilities of earlier therapies, thus enhancing its appeal for potential collaborators. Additionally, the company’s management highlights the substantial market potential of its programs, aimed at addressing major unmet medical needs, which could result in collaborative partnerships and multi-billion-dollar market opportunities. Furthermore, ALG-000184 has shown durable viral suppression in chronic hepatitis B treatment, reinforcing Aligos’s strong position within the biopharmaceutical landscape.
Bears say
Aligos Therapeutics faces significant clinical development risks, particularly regarding the safety and efficacy of its candidate ALG-000184, which could adversely impact future study outcomes. The company also grapples with regulatory uncertainties that may arise if authorities tighten approval criteria for its therapies or shift focus towards functional cures for chronic conditions. Furthermore, financing concerns loom as Aligos has a cash runway extending into the second half of 2026, coupled with the potential need for additional equity issuance to fund upcoming Phase 2b and Phase 3 studies.
This aggregate rating is based on analysts' research of Aligos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Aligos Therapeutics (ALGS) Analyst Forecast & Price Prediction
Start investing in Aligos Therapeutics (ALGS)
Order type
Buy in
Order amount
Est. shares
0 shares